Kenneth Peters, MD
Urology · Royal Oak, MINPI 1417948944
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Urovant Sciences Inc at 30.1% of the total. 2025 is the largest year on record at $11,476, 3.5 times the $3,320 reported in 2019. Among urology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $247.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urovant Sciences Inc$8K
- Coloplast$7K
- Medtronic$6K
- Boston Scientific$2K
- Purdue Pharma L.p.$1K
- Janssen Research & Development, LLC$833
- plus $3K from 23 others
Across 99 payments — averaging $5760.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$121K
- Coloplast$120K
- Urovant Sciences Inc$109K
- Inspire Medical Systems, Inc.$95K
- Ironwood Pharmaceuticals, Inc$85K
- Medtronic$17K
- plus $23K from 2 others
What the payments were for
- Consulting fees$16,67060%
- Speaking & faculty fees$3,75013%
- Grants$1,5005%
- Travel & lodging$2,81710%
- Food & beverage$2,93110%
- Education$2571%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urovant Sciences Inc | 2 | $8,408 |
| Coloplast | 17 | $6,871 |
| Medtronic(2 entities) | 25 | $5,857 |
| Boston Scientific | 4 | $1,569 |
| Purdue Pharma L.p. | 1 | $1,230 |
| Janssen Research & Development, LLC | 1 | $833 |
| Minze Health, Inc | 1 | $825 |
| Inspire Medical Systems, Inc. | 2 | $564 |
| Stimwave Technologies Incorporated | 2 | $436 |
| Astellas Pharma US Inc | 11 | $336 |
| AbbVie(2 entities) | 13 | $216 |
| Axonics, Inc. | 8 | $176 |
| C. R. Bard, Inc. & Subsidiaries | 8 | $125 |
| Laborie Medical Technologies Corp. | 1 | $82 |
| Contura, Inc. | 1 | $77 |
| Olympus America Inc. | 1 | $51 |
| Rochester Medical Corporation | 2 | $44 |
| Curonix LLC | 1 | $27 |
| Johnson & Johnson | 2 | $27 |
| Merck | 1 | $23 |
| 180 Medical, Inc. | 1 | $21 |
| Dendreon Pharmaceuticals LLC | 1 | $19 |
| AMAG Pharmaceuticals, Inc. | 1 | $18 |
| Clarus Therapeutics Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Baxter Healthcare | 1 | $16 |
| Smith+Nephew | 1 | $15 |
| Sagent Pharmaceuticals | 1 | $13 |
| Tolmar Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$5,240
- GENERAL FEMALE SUI$1,500
- Minze Homeflow$825
- Inspire Upper Airway Stimulation System$525
- GEMTESA$150
How this compares
$27,926 in reported general payments places this provider in the 90th percentile of 400 urology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 34 | $30,028 |
| Cyclosporine | 23 | $16,762 |
| Cyclosporine ModifiedCyclosporine, Modified | 70 | $7,185 |
| Estradiol | 81 | $5,193 |
| Methenamine Hippurate | 18 | $2,498 |
| Trospium Chloride | 17 | $1,729 |
| Desmopressin Acetate | 11 | $863 |
| Tamsulosin Hcl | 22 | $371 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $311 |
| Hydroxyzine Hcl | 19 | $212 |
| Diazepam | 29 | $138 |
| Tramadol Hcl | 13 | $137 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 27 | $125 |
| Cephalexin | 11 | $105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $336 | $30,02834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 400 urology providers in Michigan.
Other urology in Royal Oak
- Richard BennettRoyal Oak$361K
- Adam GadzinskiRoyal Oak$22K
- Ashok ReddySterling Heights$4.9M
- William RobertsAnn Arbor$973K
- Kenneth KernenTroy$910K
- William JohnstonLivonia$675K
- Jason HafronWest Bloomfield$490K
- Khurshid GhaniAnn Arbor$413K
- Ryan NelsonUtica$296K
- Casey DauwAnn Arbor$188K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.